Table 1.
Baseline characteristics of the series studied by study group
| Study groups | FP/SAL | BDP/FORM | BUD/FORM | FF/VI | FP/FORM | P value |
| Patients, n (%) | 996 (31.1) | 917 (28.6) | 802 (25.0) | 263 (8.2) | 225 (7.0) | |
| Sociodemographic features | ||||||
| Mean age, years | 52.3 (19.3) | 53.0 (18.5) | 51.0 (16.8) | 52.5 (17.7) | 52.8 (17.1) | 0.245 |
| Female gender, % | 60.0 | 61.1 | 61.6 | 61.6 | 60.4 | 0.968 |
| General comorbidity | ||||||
| Mean diagnoses | 6.8 (3.9) | 6.4 (3.9) | 6.2 (3.6) | 6.3 (3.6) | 6.8 (3.8) | 0.075 |
| Charlson Comorbidity Index | 0.8 (0.8) | 0.7 (0.8) | 0.7 (0.6) | 0.7 (0.8) | 0.8 (0.9) | 0.097 |
| Mean RUB | 3.0 (0.7) | 2.9 (0.7) | 2.9 (0.8) | 3.0 (0.8) | 2.9 (0.7) | 0.198 |
| 1 (very low comorbidity), % | 4.1 | 3.6 | 8.2 | 6.1 | 4.9 | |
| 2 (low comorbidity), % | 10.3 | 20.4 | 12.5 | 13.3 | 12.0 | |
| 3 (moderate comorbidity), % | 71.1 | 65.5 | 63.1 | 56.7 | 67.6 | |
| 4 (high comorbidity), % | 14.0 | 9.9 | 15.8 | 23.6 | 14.7 | |
| 5 (very high comorbidity), % | 0.5 | 0.5 | 0.4 | 0.4 | 0.9 | 0.111 |
| Associated comorbidity, % | ||||||
| High blood pressure | 29.9 | 28.9 | 29.1 | 29.3 | 29.3 | 0.991 |
| Diabetes mellitus | 13.4 | 12.8 | 13.0 | 13.3 | 12.9 | 0.996 |
| Dyslipidaemia | 41.0 | 41.3 | 41.3 | 40.7 | 39.8 | 0.811 |
| Obesity | 27.9 | 28.6 | 27.7 | 26.2 | 27.6 | 0.963 |
| Ischaemic heart disease | 4.3 | 4.0 | 4.0 | 3.8 | 4.0 | 0.994 |
| Cerebrovascular accident | 7.3 | 7.0 | 7.0 | 6.8 | 6.7 | 0.995 |
| Cardiovascular event | 11.8 | 9.2 | 9.1 | 10.6 | 10.2 | 0.272 |
| Depressive syndrome | 19.5 | 19.6 | 20.2 | 20.9 | 20.4 | 0.982 |
| Malignancies | 10.9 | 10.5 | 10.3 | 11.8 | 10.2 | 0.964 |
| Allergic rhinitis | 61.7 | 63.1 | 61.8 | 63.5 | 62.2 | 0.959 |
| Nasal polyposis | 15.5 | 15.4 | 15.3 | 14.1 | 16.4 | 0.969 |
| Gastro-oesophageal reflux | 39.1 | 40.9 | 38.0 | 41.1 | 40.9 | 0.739 |
| Asthma severity, % | ||||||
| Intermittent | 13.0 | 14.9 | 12.0 | 12.5 | 12.0 | |
| Mild persistent | 25.0 | 21.5 | 24.6 | 25.1 | 25.3 | |
| Moderate persistent | 44.5 | 45.1 | 45.3 | 43.3 | 45.4 | |
| Severe persistent | 17.6 | 18.4 | 18.2 | 19.0 | 18.2 | 0.844 |
| Other variables | ||||||
| BMI, kg/m2 | 28.4 (5) | 28.6 (5.0) | 28.4 (5.0) | 28.6 (5.5) | 27.9 (4.9) | 0.228 |
| FEV1, % predicted | 74.8 | 74.3 | 74.7 | 74.6 | 74.8 | 0.954 |
Values expressed as percentage or mean (SD, standard deviation), p: statistical significance.
BDP/FORM, beclomethasone /formoterol; BMI, body mass index; BUD/FORM, budesonide/formoterol; FEV1, forced expiratory volume in 1 s.; FF/VI, fluticasone furoate/vilanterol; FP/FORM, fluticasone propionate /formoterol; FP/SAL, fluticasone propionate/salmeterol; RUB, resource utilisation bands.